Vildagliptin

Rediff.com » News » Vildagliptin

News for Vildagliptin

Business

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Drug sale volumes are almost stuck at pre-pandemic levels but price growth has improved value, data from market research agency Pharmarack AWACS showed. Illustration: Uttam Ghosh/Rediff.com The......

Price relief for diabetes patients as drugs go off patent

At least two key drugs in the gliptin category have already gone off patent and cheaper variants are crowding the market. Also, several patent expiries are round the corner for the newest category......

Prices of key diabetes, cancer drugs may drop by 25%

A recent report has suggested that future patent expires in the cardiac and anti-diabetes space would form a good opportunity for smaller firms, given their franchise in these segments. The next......

Novartis sues Biocon for patent breach

In what may turn out to be another major patent litigation between a multinational and a local pharmaceutical company, Swiss giant Novartis has dragged Biocon to court for allegedly infringing......

MNCs' diabetes drug patents worry experts

Even as India is fast turning into the diabetes capital of the world, multinational drug companies are busy patenting new-generation diabetes medicines for exclusive marketing rights in the......

Rediff News

Vildagliptin

News for Vildagliptin

Drug sales stuck at pre-pandemic level, price rise shapes market growth

Price relief for diabetes patients as drugs go off patent

Prices of key diabetes, cancer drugs may drop by 25%

Novartis sues Biocon for patent breach

MNCs' diabetes drug patents worry experts

Top Coverage News

World Test Championship 2023

Manipur's Tragedy

IPL 2023

Sri Lanka's Tour of India 2023

GUJARAT, HIMACHAL GO TO POLLS